echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > Clin Cancer Res: New prognosmation markers and therapeutic targets for bile tube cancer - IL6 and IL6R!

    Clin Cancer Res: New prognosmation markers and therapeutic targets for bile tube cancer - IL6 and IL6R!

    • Last Update: 2020-10-04
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Bile tube cancer (BTC) is a rare gastrointestinal malignancies with poor prognosmation and often accompanied by inflammation.
    Andersen et al. assessed the prognosmative value of IL6 and YKL-40 and CA19-9 before and after palliative chemotherapy, and studied in mice whether IL6R inhibition combined gissethamin could prolong the chemotherapy sensitivity period.
    the study included 452 late-stage (locally late-stage or metastasis) BTC Danish patients in six clinical trials (2004-2017).
    levels of serum CA199, IL6 and YKL-40 were detected before and after palliative chemotherapy.
    the correlation between candidate biomarkers and progressive survival (PFS) and overall survival (OS) was analyzed using single-variable and multivariable Cox models.
    in patients with advanced BTC, ca199, IL6, and YKL-40 pre-treatment high levels and elevated levels during treatment were associated with shorter PFS and OS.
    IL6 provides independent prognossis information, independent of tumor location and serum CA199 levels.
    ROC analysis shows that IL6 and YKL-40 can predict very short OS (-lt;6 months), while CA199 is best suited to predict OS in patients with OS over 1.5 years.
    in BTC's transplanted tumor mouse model, the use of anti-IL6R combined gixitrabin therapy significantly slowed tumor growth compared to gixitrabin monotherapy.
    , serum IL6 and YKL-40 are potential new prognosmical biomarkers for bile tube cancer.
    IL6 provides independent prognosm information and may be superior to CA199.
    addition, consideration should be given to anti-IL6R as a new treatment option to maintain the sensitivity of BTC patients to Gissitham treatment.
    .
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.